The Claim
In adults with chronic kidney disease, febuxostat produces a greater reduction in serum uric acid levels than allopurinol, with a mean decrease of 0.92 mg/dL over 3 months and a higher proportion of patients maintaining serum uric acid below 6 mg/dL for more than 80% of follow-up time, but neither drug alters the rate of estimated glomerular filtration rate decline over 2.5 years.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with chronic kidney disease, febuxostat lowers uric acid levels more than allopurinol over 3 months and keeps more patients below a target uric acid level for most of the time, but neither drug slows the decline in kidney function over 2.5 years.
See the scientific wording
In adults with chronic kidney disease, febuxostat leads to a greater reduction in serum uric acid levels compared to allopurinol, with a mean decrease of 0.92 mg/dL per 3 months, and a higher proportion of patients maintaining serum uric acid below 6 mg/dL for over 80% of follow-up time, but neither drug significantly alters the rate of estimated glomerular filtration rate decline over 2.5 years of observation.
Febuxostat blocks the enzyme that makes uric acid more completely than allopurinol, so less uric acid is made in the body. This lowers uric acid levels in the blood more than allopurinol does. Neither drug changes how the kidneys filter blood over time.
What the research says
1 studyIn people with kidney disease, febuxostat lowers uric acid more than allopurinol, but both drugs protect the kidneys equally — neither slows kidney damage better than the other.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.